Licensing, Acquisitions and other Arrangements (Tables)

9 Months Ended

Sep. 30, 2015

Licensing, Acquisitions and Other Arrangements

Schedule of consideration paid

(in millions)
Fair value of AbbVie common stock issued to Pharmacyclics stockholders	$ 8,405
Cash consideration paid to Pharmacyclics stockholders	11,749
Cash consideration paid to Pharmacyclics equity award holders	616
Total consideration	$ 20,770

Schedule of fair value of the assets acquired and liabilities assumed

(in millions)
Assets acquired and liabilities assumed
Cash and equivalents	$ 877
Short-term investments	11
Accounts and other receivables	106
Inventories	492
Other assets	212
Intangible assets
Definite-lived developed product rights	4,590
Definite-lived license agreements	6,780
Indefinite-lived research and development	7,180
Accounts payable and accrued liabilities	(381	)
Deferred income taxes	(6,453	)
Other long-term liabilities	(254	)
Total identifiable net assets	13,160
Goodwill	7,610
Total assets acquired and liabilities assumed	$ 20,770

Schedule of pro forma combined results of operations

	Three months ended September 30,		Nine months ended September 30,
(in millions, except per share information)	2015	2014	2015	2014
Net revenues	$ 5,944	$ 5,226	$ 16,815	$ 14,947
Net earnings	$ 1,332	$ 351	$ 3,780	$ 1,706
Basic earnings per share	$ 0.81	$ 0.20	$ 2.23	$ 0.99
Diluted earnings per share	$ 0.80	$ 0.20	$ 2.22	$ 0.98